In Vitro Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli Isolated from Patients with Intra- Abdominal Infections Worldwide: The 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART)
- 1 December 2005
- journal article
- Published by Mary Ann Liebert Inc in Surgical Infections
- Vol. 6 (4) , 439-448
- https://doi.org/10.1089/sur.2005.6.439
Abstract
The Study for Monitoring Antimicrobial Resistance Trends (SMART) was begun in 2002 to monitor international drug-resistance patterns among aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections. In 2002, 40 medical centers from 17 countries collected consecutive non-duplicate isolates from intra-abdominal infections for susceptibility testing against 12 antimicrobial agents using the broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards). A total of 3,134 aerobic and facultative gram-negative bacilli were isolated. Enterobacteriaceae accounted for 82% of the total and were most consistently susceptible to amikacin and the carbapenems. Escherichia coli (45%) and Klebsiella spp. (17%) were the most common species. The susceptibility rates of these organisms to the 12 antimicrobial agents differed among geographic regions, with isolates from the Asia/Pacific and Latin American regions usually having the highest rates of resistance. Ampicillin/sulbactam was the agent least frequently active against E. coli (56% susceptible) and Klebsiella spp. (73% susceptible). Extended-spectrum beta-lactamases (ESBLs) were detected phenotypically in 7% of E. coli, 13% of Klebsiella spp., and 18% of Enterobacter spp. Producers of ESBL overall had a more antibiotic-resistant profile than non-producers but were usually susceptible to carbapenems. Antimicrobial resistance rates among gram-negative bacilli isolated from intra-abdominal infections differed among geographic regions. The carbapenems were consistently active in vitro against Enterobacteriaceae worldwide, including ESBL producers.Keywords
This publication has 17 references indexed in Scilit:
- Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002)Diagnostic Microbiology and Infectious Disease, 2004
- Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American Surveillance study (2000–2002)Annals of Clinical Microbiology and Antimicrobials, 2004
- Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection controlJournal of Infection, 2003
- Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal InfectionsClinical Infectious Diseases, 2003
- The need for antimicrobial resistance surveillanceJournal of Antimicrobial Chemotherapy, 2002
- The Surgical Infection Society Guidelines on Antimicrobial Therapy for Intra-Abdominal Infections: An Executive SummarySurgical Infections, 2002
- Determining the value of antimicrobial surveillance programsDiagnostic Microbiology and Infectious Disease, 2001
- The MYSTIC (meropenem yearly susceptibility test information collection) programmeInternational Journal of Antimicrobial Agents, 1999
- Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)Antimicrobial Agents and Chemotherapy, 1998
- A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander ProjectJournal of Antimicrobial Chemotherapy, 1996